ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, April 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (the "Company") (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 53,800 of the Company's common shares to six new employees on April 1, 2024 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08. The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.
瑞士洛桑，2024年4月1日（环球新闻专线）——ADC Therapeutics SA（“公司”）（纽约证券交易所代码：ADCT）今天宣布，公司已于2024年4月1日向六名新员工授予了购买公司总共53,800股普通股的期权（每股均为 “补助金”）。这些补助金是作为对雇员就业的物质刺激而提供的。根据公司的激励计划，这些补助金由公司董事会薪酬委员会批准，旨在激励和奖励接受者保持最高水平，为公司的成功做出重大贡献。补助金是根据纽约证券交易所上市公司手册第303A.08条规定的就业激励豁免发放的。该公司根据第303A.08条发布本新闻稿。补助金应在拨款日一周年之日归属并可行使 25%，1/48第四 此后在授予之日的每个月周年纪念日受奖励的股票总数，因此，全部奖励将自授予之日起的四周年归属，前提是继续在公司工作。
About ADC Therapeutics
关于ADC疗法
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics（纽约证券交易所代码：ADCT）是抗体药物偶联物（ADC）领域的商业阶段全球领导者和先驱者。该公司正在推进其专有的ADC技术，以改变血液系统恶性肿瘤和实体瘤患者的治疗模式。
ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
ADC Therapeutics的CD19靶向的ADC ZYNLONTA（loncastuximab tesirine-lpyl）获得了美国食品药品管理局的加速批准和欧盟委员会的有条件批准，用于治疗两条或更多线路全身治疗后的复发或难治性弥漫性大B细胞淋巴瘤。ZYNLONTA还正在与其他药物联合开发中，并已进入早期治疗领域。除了 ZYNLONTA 之外，ADC Therapeutics 还有多个 ADC 正在进行临床和临床前开发。
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit and follow the Company on LinkedIn.
ADC Therapeutics总部位于瑞士洛桑（Biopole），在伦敦、旧金山湾区和新泽西州开展业务。如需了解更多信息，请访问并在 LinkedIn 上关注公司。
ZYNLONTA is a registered trademark of ADC Therapeutics SA.
ZYNLONTA 是 ADC Therapeutics SA 的注册商标。
CONTACT:
Investors and Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040
联系人：
投资者和媒体
妮可·莱利
ADC 疗法
Nicole.Riley@adctherapeutics.com
+1 862-926-9040
译文内容由第三方软件翻译。